Description A phase 2, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of ponsegromab in patients with cancer, cachexia, and elevated concentrations of GDF-15, followed by an optional open-label treatment period

Trial overview


Non-small cell lung cancer, Pancreatic cancer, colorectal cancer

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of non-small cell lung, pancreatic, colorectal cancer
  • Cachexia defined by Fearon criteria of weight loss
  • Serum GDF-15 concentrations
  • Signed informed consent
  • ECOG PS ≤3

Key Exclusion Criteria:

  • Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
  • Current active reversible causes of decreased food intake.
  • Cachexia caused by other reasons.
  • History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.
  • inadequate renal or liver function

Study details

A 12 week double blind study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

During the initial 12-week treatment period (Part A), a total of 3 doses of ponsegromab or placebo will be administered 4 weeks apart subcutaneously. Each dose contains two injections. Part B is an optional open-label treatment period consisting of ponsegromab administered every 4 weeks subcutaneously for up to one year. Part B does not include placebo.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.